These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25881000)

  • 1. Serotype-specific Binding Properties and Nanoparticle Characteristics Contribute to the Immunogenicity of rAAV1 Vectors.
    Ferrand M; Da Rocha S; Corre G; Galy A; Boisgerault F
    Mol Ther; 2015 Jun; 23(6):1022-1033. PubMed ID: 25881000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors.
    Lu Y; Song S
    Proc Natl Acad Sci U S A; 2009 Oct; 106(40):17158-62. PubMed ID: 19805176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early interaction of adeno-associated virus serotype 8 vector with the host immune system following intramuscular delivery results in weak but detectable lymphocyte and dendritic cell transduction.
    Gernoux G; Guilbaud M; Dubreil L; Larcher T; Babarit C; Ledevin M; Jaulin N; Planel P; Moullier P; Adjali O
    Hum Gene Ther; 2015 Jan; 26(1):1-13. PubMed ID: 25333770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrinsic transgene immunogenicity gears CD8(+) T-cell priming after rAAV-mediated muscle gene transfer.
    Carpentier M; Lorain S; Chappert P; Lalfer M; Hardet R; Urbain D; Peccate C; Adriouch S; Garcia L; Davoust J; Gross DA
    Mol Ther; 2015 Apr; 23(4):697-706. PubMed ID: 25492560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction.
    Muhuri M; Zhan W; Maeda Y; Li J; Lotun A; Chen J; Sylvia K; Dasgupta I; Arjomandnejad M; Nixon T; Keeler AM; Manokaran S; He R; Su Q; Tai PWL; Gao G
    Front Immunol; 2021; 12():674242. PubMed ID: 33995418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged gene expression in muscle is achieved without active immune tolerance using microrRNA 142.3p-regulated rAAV gene transfer.
    Boisgerault F; Gross DA; Ferrand M; Poupiot J; Darocha S; Richard I; Galy A
    Hum Gene Ther; 2013 Apr; 24(4):393-405. PubMed ID: 23427817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.
    Brantly ML; Chulay JD; Wang L; Mueller C; Humphries M; Spencer LT; Rouhani F; Conlon TJ; Calcedo R; Betts MR; Spencer C; Byrne BJ; Wilson JM; Flotte TR
    Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16363-8. PubMed ID: 19706466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.
    McIntosh JH; Cochrane M; Cobbold S; Waldmann H; Nathwani SA; Davidoff AM; Nathwani AC
    Gene Ther; 2012 Jan; 19(1):78-85. PubMed ID: 21716299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy.
    Ertl HCJ; High KA
    Hum Gene Ther; 2017 Apr; 28(4):328-337. PubMed ID: 28042943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intradermal Immunization with rAAV1 Vector Induces Robust Memory CD8
    Ghenassia A; Gross DA; Lorain S; Tros F; Urbain D; Benkhelifa-Ziyyat S; Charbit A; Davoust J; Chappert P
    Mol Ther; 2017 Oct; 25(10):2309-2322. PubMed ID: 28720467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors.
    Manning WC; Zhou S; Bland MP; Escobedo JA; Dwarki V
    Hum Gene Ther; 1998 Mar; 9(4):477-85. PubMed ID: 9525309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans.
    Gernoux G; Gruntman AM; Blackwood M; Zieger M; Flotte TR; Mueller C
    Mol Ther; 2020 Mar; 28(3):747-757. PubMed ID: 31982038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors.
    Chen S; Kapturczak M; Loiler SA; Zolotukhin S; Glushakova OY; Madsen KM; Samulski RJ; Hauswirth WW; Campbell-Thompson M; Berns KI; Flotte TR; Atkinson MA; Tisher CC; Agarwal A
    Hum Gene Ther; 2005 Feb; 16(2):235-47. PubMed ID: 15761263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.
    Mueller C; Chulay JD; Trapnell BC; Humphries M; Carey B; Sandhaus RA; McElvaney NG; Messina L; Tang Q; Rouhani FN; Campbell-Thompson M; Fu AD; Yachnis A; Knop DR; Ye GJ; Brantly M; Calcedo R; Somanathan S; Richman LP; Vonderheide RH; Hulme MA; Brusko TM; Wilson JM; Flotte TR
    J Clin Invest; 2013 Dec; 123(12):5310-8. PubMed ID: 24231351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.
    Aldrich WA; Ren C; White AF; Zhou SZ; Kumar S; Jenkins CB; Shaw DR; Strong TV; Triozzi PL; Ponnazhagan S
    Gene Ther; 2006 Jan; 13(1):29-39. PubMed ID: 16136165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism.
    Muzyczka N; Warrington KH
    Hum Gene Ther; 2005 Apr; 16(4):408-16. PubMed ID: 15871672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors.
    Sarukhan A; Soudais C; Danos O; Jooss K
    J Gene Med; 2001; 3(3):260-70. PubMed ID: 11437331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models.
    Davidoff AM; Gray JT; Ng CY; Zhang Y; Zhou J; Spence Y; Bakar Y; Nathwani AC
    Mol Ther; 2005 Jun; 11(6):875-88. PubMed ID: 15922958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity.
    Xiao Y; Muhuri M; Li S; Qin W; Xu G; Luo L; Li J; Letizia AJ; Wang SK; Chan YK; Wang C; Fuchs SP; Wang D; Su Q; Nahid MA; Church GM; Farzan M; Yang L; Wei Y; Desrosiers RC; Mueller C; Tai PW; Gao G
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31112525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression.
    Urabe M; Xin KQ; Obara Y; Nakakura T; Mizukami H; Kume A; Okuda K; Ozawa K
    Mol Ther; 2006 Apr; 13(4):823-8. PubMed ID: 16473554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.